Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis
- PMID: 23714268
- DOI: 10.1111/resp.12130
Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis
Abstract
Background and objective: To explore the effect of long-term therapy with azithromycin in regards to airway oxidative stress markers in exhaled breath condensate (EBC) of adult patients with stable non-cystic fibrosis (CF) bronchiectasis.
Methods: Open-label prospective study of 30 patients randomized to azithromycin 250 mg three times per week during 3 months (16 patients) or control (14 patients). Primary outcome were changes in nitric oxide, 8-isoprostane, pH, nitrites and nitrates in EBC. Secondary outcomes were changes in exacerbation rates, dyspnoea (Borg scale), sputum volume (cc), sputum colour (15-point scale), bacterial infection, health-related quality of life (St George's Respiratory Questionnaire), lung function and radiological extension.
Results: Azithromycin produced a significant decrease in sputum volume (8.9 (1.8) mL vs 2.1 (3.4) mL) and number of exacerbations (0.1 (0.6) vs 1.2 (0.9)). Dyspnoea (0.4 (0.1) vs 0.1 (0.2)) and health-related quality of life also improved after therapy. However, oxidative stress markers in EBC, systemic inflammatory markers as well as functional respiratory tests did not differ from the control group after therapy. A post-hoc analysis comparing patients infected or not with Pseudomonas aeruginosa revealed that these effects were more pronounced in infected patients. In this subgroup, treatment was followed by a significant reduction in sputum volume, number of exacerbations, dyspnoea and St George's Respiratory Questionnaire total score. Of all airway oxidative stress markers, only nitrates in EBC were reduced after therapy.
Conclusions: Long-term azythromicin treatment has some clinical benefits in patients with non-CF stable bronchiectasis, but it does not affect airway oxidative stress markers.
Keywords: airway oxidative stress marker; azithromycin; bronchiectasis; inflammation; long-term therapy.
© 2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology.
Comment in
-
Oxidative stress and macrolides in bronchiectasis--exhaling few clues.Respirology. 2013 Oct;18(7):1037-8. doi: 10.1111/resp.12161. Respirology. 2013. PMID: 23890203 No abstract available.
Similar articles
-
[Inflammation markers in the exhaled air of patients with bronchiectasis unassociated with cystic fibrosis].Arch Bronconeumol. 2009 Dec;45(12):597-602. doi: 10.1016/j.arbres.2009.09.007. Epub 2009 Oct 28. Arch Bronconeumol. 2009. PMID: 19875219 Spanish.
-
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.Lancet. 2012 Aug 18;380(9842):660-7. doi: 10.1016/S0140-6736(12)60953-2. Lancet. 2012. PMID: 22901887 Clinical Trial.
-
Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.JAMA. 2013 Mar 27;309(12):1251-9. doi: 10.1001/jama.2013.1937. JAMA. 2013. PMID: 23532241 Clinical Trial.
-
Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials.Expert Rev Respir Med. 2018 Sep;12(9):769-782. doi: 10.1080/17476348.2018.1503540. Epub 2018 Aug 3. Expert Rev Respir Med. 2018. PMID: 30025482 Review.
-
The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies.J Cardiothorac Surg. 2022 Oct 11;17(1):266. doi: 10.1186/s13019-022-01882-y. J Cardiothorac Surg. 2022. PMID: 36221151 Free PMC article. Review.
Cited by
-
When and how ruling out cystic fibrosis in adult patients with bronchiectasis.Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):29. doi: 10.1186/s40248-018-0142-7. eCollection 2018. Multidiscip Respir Med. 2018. PMID: 30151190 Free PMC article. Review.
-
Bronchiectasis.BMJ Clin Evid. 2015 Feb 25;2015:1507. BMJ Clin Evid. 2015. PMID: 25715965 Free PMC article. Review.
-
A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults.Eur Respir Rev. 2019 Mar 14;28(151):180108. doi: 10.1183/16000617.0108-2018. Print 2019 Mar 31. Eur Respir Rev. 2019. PMID: 30872400 Free PMC article.
-
Year in review 2013: Acute lung injury, interstitial lung diseases, sleep and physiology.Respirology. 2014 Apr;19(3):428-37. doi: 10.1111/resp.12254. Epub 2014 Feb 21. Respirology. 2014. PMID: 24708032 Free PMC article. Review. No abstract available.
-
Inflammation and Oxidation Biomarkers in Patients with Cystic Fibrosis: The Influence of Azithromycin.Eurasian J Med. 2017 Jun;49(2):118-123. doi: 10.5152/eurasianjmed.2017.17010. Eurasian J Med. 2017. PMID: 28638254 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical